The CDK1 inhibitor, Ro-3306, is a potential antiviral candidate against influenza virus infection

Zhao, Lei; Yan, Yunzheng; Dai, Qingsong; Wang, Zihao; Yin, Ji‐Ye; Xu, Yijie; Wang, Zhuang; Guo, Xiaojia; Li, Wei; Cao, Ruiyuan; Zhong, Wu

doi:10.1016/j.antiviral.2022.105296

Cited by 6 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As shown in Table 3 , the lower the CMap connectivity score, the more likely it is to be a potential therapeutic agent. RO-3306 is an ATP competitive cyclin-dependent kinase (CDKs) inhibitor that explicitly suppresses CDK's activity and, thereby, suppresses cell-cycle progression [ 87 ]. CDKs are serine/threonine kinases that play a central role in regulating cell-cycle progression by interacting with the cyclin subunits [ 88 ].…”

Section: Discussionmentioning

confidence: 99%

Shared peripheral blood biomarkers for Alzheimer’s disease, major depressive disorder, and type 2 diabetes and cognitive risk factor analysis

Geng

Liu

Deng

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Shared peripheral blood biomarkers for Alzheimer’s disease, major depressive disorder, and type 2 diabetes and cognitive risk factor analysis

Geng

Liu

Deng

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…ABX464 exerts its action by preventing the Rev-mediated export of US transcripts to the cytoplasm and thus inhibits HIV-1 replication [61] . Reported anti-IAV agents mainly target specific splicing events [62,63] . Besides, drugs against other viruses, parasites, and fungi infections are also documented [64–71] .…”

Section: Targeted Agents For As In Infectious Diseasesmentioning

confidence: 99%

“…[61] Reported anti-IAV agents mainly target specific splicing events. [62,63] Besides, drugs against other viruses, parasites, and fungi infections are also documented. [64][65][66][67][68][69][70][71] Of note, drugs targeting bacterial infection have not been reported.…”

Section: Targeted Agents For As In Infectious Diseasesmentioning

confidence: 99%

Roles of alternative splicing in infectious diseases: from hosts, pathogens to their interactions

Lyu

Lai

Wang

et al. 2023

Chinese Medical Journal

View full text Add to dashboard Cite

Alternative splicing (AS) is an evolutionarily conserved mechanism that removes introns and ligates exons to generate mature messenger RNAs (mRNAs), extremely improving the richness of transcriptome and proteome. Both mammal hosts and pathogens require AS to maintain their life activities, and inherent physiological heterogeneity between mammals and pathogens makes them adopt different ways to perform AS. Mammals and fungi conduct a two-step transesterification reaction by spliceosomes to splice each individual mRNA (named cis-splicing). Parasites also use spliceosomes to splice, but this splicing can occur among different mRNAs (named trans-splicing). Bacteria and viruses directly hijack the host's splicing machinery to accomplish this process. Infection-related changes are reflected in the spliceosome behaviors and the characteristics of various splicing regulators (abundance, modification, distribution, movement speed, and conformation), which further radiate to alterations in the global splicing profiles. Genes with splicing changes are enriched in immune-, growth-, or metabolism-related pathways, highlighting approaches through which hosts crosstalk with pathogens. Based on these infection-specific regulators or AS events, several targeted agents have been developed to fight against pathogens. Here, we summarized recent findings in the field of infection-related splicing, including splicing mechanisms of pathogens and hosts, splicing regulation and aberrant AS events, as well as emerging targeted drugs. We aimed to systemically decode host–pathogen interactions from a perspective of splicing. We further discussed the current strategies of drug development, detection methods, analysis algorithms, and database construction, facilitating the annotation of infection-related splicing and the integration of AS with disease phenotype.

show abstract

“…This CDK1 inhibitor displayed substantial antiviral activity against all tested influenza viruses without having a cytotoxic effect on the host’s cell. It was also proven to be effective against influenza strains resistant to oseltamivir [ 100 ].…”

Section: Future Of the Influenza Treatmentmentioning

confidence: 99%

Evolution of Influenza Viruses—Drug Resistance, Treatment Options, and Prospects

Smyk

Szydłowska

Szulc

et al. 2022

IJMS

View full text Add to dashboard Cite

Viral evolution refers to the genetic changes that a virus accumulates during its lifetime which can arise from adaptations in response to environmental changes or the immune response of the host. Influenza A virus is one of the most rapidly evolving microorganisms. Its genetic instability may lead to large changes in its biological properties, including changes in virulence, adaptation to new hosts, and even the emergence of infectious diseases with a previously unknown clinical course. Genetic variability makes it difficult to implement effective prophylactic programs, such as vaccinations, and may be responsible for resistance to antiviral drugs. The aim of the review was to describe the consequences of the variability of influenza viruses, mutations, and recombination, which allow viruses to overcome species barriers, causing epidemics and pandemics. Another consequence of influenza virus evolution is the risk of the resistance to antiviral drugs. Thus far, one class of drugs, M2 protein inhibitors, has been excluded from use because of mutations in strains isolated in many regions of the world from humans and animals. Therefore, the effectiveness of anti-influenza drugs should be continuously monitored in reference centers representing particular regions of the world as a part of epidemiological surveillance.

show abstract

The CDK1 inhibitor, Ro-3306, is a potential antiviral candidate against influenza virus infection

Cited by 6 publications

References 32 publications

Shared peripheral blood biomarkers for Alzheimer’s disease, major depressive disorder, and type 2 diabetes and cognitive risk factor analysis

Shared peripheral blood biomarkers for Alzheimer’s disease, major depressive disorder, and type 2 diabetes and cognitive risk factor analysis

Roles of alternative splicing in infectious diseases: from hosts, pathogens to their interactions

Evolution of Influenza Viruses—Drug Resistance, Treatment Options, and Prospects

Contact Info

Product

Resources

About